Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Agios Pharmaceuticals's Enterprise Value is $1,365.25 Mil.
Agios Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-360.60 Mil. Therefore, Agios Pharmaceuticals's EV-to-OCF for today is -3.79.
The historical rank and industry rank for Agios Pharmaceuticals's EV-to-OCF or its related term are showing as below:
AGIO'
s EV-to-OCF Range Over the Past 10 Years
Min: -122.55 Med: -5.23 Max: 46.35
Current: -3.79
During the past 13 years, the highest EV-to-OCF of Agios Pharmaceuticals was 46.35. The lowest was -122.55. And the median was -5.23.
AGIO's EV-to-OCF is ranked better than 51.35% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs AGIO: -3.79
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Agios Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Agios Pharmaceuticals's share price for today is $32.69.
Agios Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agios Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's EV-to-OCF falls into.
Agios Pharmaceuticals's current Enterprise Value is $1,365.25 Mil.
Agios Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-360.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (AGIO) has a EV-to-OCF of -3.79 as of Aug. 11, 2026. According to the industry distribution chart, Agios Pharmaceuticals ranks #684 out of 1406 companies in the Biotechnology industry, placing it in the top 48.6%.
Is Agios Pharmaceuticals' EV-to-OCF too high?
Agios Pharmaceuticals' current EV-to-OCF is -3.79. Based on the distribution chart, Agios Pharmaceuticals ranks #684 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Agios Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' EV-to-OCF compare to BHVN and VRDN?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #684 out of 1406 companies for EV-to-OCF. This puts Agios Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Agios Pharmaceuticals's current EV-to-OCF is -3.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (AGIO) is currently considered Possible Value Trap. The stock's GF Value™ is $109.22, compared to a current price of $32.69 — trading 70.1% below its estimated fair value. The current EV-to-OCF is -3.79. Agios Pharmaceuticals' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Agios Pharmaceuticals (AGIO), the current EV-to-OCF is -3.79 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of $32.69 is trading 70.1% below its estimated GF Value™ of $109.22.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for AGIO:
EV-to-OCF: -3.79
GF Value™: $109.22 vs. price of $32.69 (70.1% below fair value)
No single metric tells the full story. See the AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
48GF Score
Get the complete analysis for AGIO
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGIO has been successfully added to your 
